172 related articles for article (PubMed ID: 21287529)
1. Effect of the histone deacetylase inhibitor SNDX-275 on Fas signaling in osteosarcoma cells and the feasibility of its topical application for the treatment of osteosarcoma lung metastases.
Koshkina NV; Rao-Bindal K; Kleinerman ES
Cancer; 2011 Aug; 117(15):3457-67. PubMed ID: 21287529
[TBL] [Abstract][Full Text] [Related]
2. The histone deacetylase inhibitor, MS-275 (entinostat), downregulates c-FLIP, sensitizes osteosarcoma cells to FasL, and induces the regression of osteosarcoma lung metastases.
Rao-Bindal K; Koshkina NV; Stewart J; Kleinerman ES
Curr Cancer Drug Targets; 2013 May; 13(4):411-22. PubMed ID: 23410027
[TBL] [Abstract][Full Text] [Related]
3. The Fas/FasL Signaling Pathway: Its Role in the Metastatic Process and as a Target for Treating Osteosarcoma Lung Metastases.
Koshkina N; Yang Y; Kleinerman ES
Adv Exp Med Biol; 2020; 1258():177-187. PubMed ID: 32767242
[TBL] [Abstract][Full Text] [Related]
4. Participation of the Fas/FasL signaling pathway and the lung microenvironment in the development of osteosarcoma lung metastases.
Huang G; Nishimoto K; Yang Y; Kleinerman ES
Adv Exp Med Biol; 2014; 804():203-17. PubMed ID: 24924176
[TBL] [Abstract][Full Text] [Related]
5. MS-275 sensitizes osteosarcoma cells to Fas ligand-induced cell death by increasing the localization of Fas in membrane lipid rafts.
Rao-Bindal K; Zhou Z; Kleinerman ES
Cell Death Dis; 2012 Aug; 3(8):e369. PubMed ID: 22875006
[TBL] [Abstract][Full Text] [Related]
6. The Histone Deacetylase Inhibitor Entinostat/Syndax 275 in Osteosarcoma.
Kiany S; Harrison D; Gordon N
Adv Exp Med Biol; 2020; 1257():75-83. PubMed ID: 32483732
[TBL] [Abstract][Full Text] [Related]
7. Aerosol therapy for the treatment of osteosarcoma lung metastases: targeting the Fas/FasL pathway and rationale for the use of gemcitabine.
Gordon N; Kleinerman ES
J Aerosol Med Pulm Drug Deliv; 2010 Aug; 23(4):189-96. PubMed ID: 20528149
[TBL] [Abstract][Full Text] [Related]
8. Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemcitabine.
Gordon N; Koshkina NV; Jia SF; Khanna C; Mendoza A; Worth LL; Kleinerman ES
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4503-10. PubMed ID: 17671136
[TBL] [Abstract][Full Text] [Related]
9. The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors.
Jóna A; Khaskhely N; Buglio D; Shafer JA; Derenzini E; Bollard CM; Medeiros LJ; Illés A; Ji Y; Younes A
Exp Hematol; 2011 Oct; 39(10):1007-1017.e1. PubMed ID: 21767511
[TBL] [Abstract][Full Text] [Related]
10. VEGF165 is necessary to the metastatic potential of Fas(-) osteosarcoma cells but will not rescue the Fas(+) cells.
Jia SF; Guan H; Duan X; Kleinerman ES
J Exp Ther Oncol; 2008; 7(2):89-97. PubMed ID: 18771083
[TBL] [Abstract][Full Text] [Related]
11. Fas-negative osteosarcoma tumor cells are selected during metastasis to the lungs: the role of the Fas pathway in the metastatic process of osteosarcoma.
Koshkina NV; Khanna C; Mendoza A; Guan H; DeLauter L; Kleinerman ES
Mol Cancer Res; 2007 Oct; 5(10):991-9. PubMed ID: 17951400
[TBL] [Abstract][Full Text] [Related]
12. HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance.
Huang X; Wang S; Lee CK; Yang X; Liu B
Cancer Lett; 2011 Aug; 307(1):72-79. PubMed ID: 21497990
[TBL] [Abstract][Full Text] [Related]
13. HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via down-regulation of erbB3 expression.
Huang X; Gao L; Wang S; Lee CK; Ordentlich P; Liu B
Cancer Res; 2009 Nov; 69(21):8403-11. PubMed ID: 19826038
[TBL] [Abstract][Full Text] [Related]
14. Aerosol gemcitabine inhibits the growth of primary osteosarcoma and osteosarcoma lung metastases.
Koshkina NV; Kleinerman ES
Int J Cancer; 2005 Sep; 116(3):458-63. PubMed ID: 15800950
[TBL] [Abstract][Full Text] [Related]
15. The role of Fas/FasL in the metastatic potential of osteosarcoma and targeting this pathway for the treatment of osteosarcoma lung metastases.
Gordon N; Kleinerman ES
Cancer Treat Res; 2009; 152():497-508. PubMed ID: 20213411
[TBL] [Abstract][Full Text] [Related]
16. miR-20a Regulates FAS Expression in Osteosarcoma Cells by Modulating
Yang Y; Huang G; Zhou Z; Fewell JG; Kleinerman ES
Mol Cancer Ther; 2018 Jan; 17(1):130-139. PubMed ID: 29079708
[TBL] [Abstract][Full Text] [Related]
17. Expression of c-FLIP in pulmonary metastases in osteosarcoma patients and human xenografts.
Rao-Bindal K; Rao CK; Yu L; Kleinerman ES
Pediatr Blood Cancer; 2013 Apr; 60(4):575-9. PubMed ID: 23255321
[TBL] [Abstract][Full Text] [Related]
18. miR-20a encoded by the miR-17-92 cluster increases the metastatic potential of osteosarcoma cells by regulating Fas expression.
Huang G; Nishimoto K; Zhou Z; Hughes D; Kleinerman ES
Cancer Res; 2012 Feb; 72(4):908-16. PubMed ID: 22186140
[TBL] [Abstract][Full Text] [Related]
19. Fas expression in lung metastasis from osteosarcoma patients.
Gordon N; Arndt CA; Hawkins DS; Doherty DK; Inwards CY; Munsell MF; Stewart J; Koshkina NV; Kleinerman ES
J Pediatr Hematol Oncol; 2005 Nov; 27(11):611-5. PubMed ID: 16282894
[TBL] [Abstract][Full Text] [Related]
20. HDAC inhibition by SNDX-275 (Entinostat) restores expression of silenced leukemia-associated transcription factors Nur77 and Nor1 and of key pro-apoptotic proteins in AML.
Zhou L; Ruvolo VR; McQueen T; Chen W; Samudio IJ; Conneely O; Konopleva M; Andreeff M
Leukemia; 2013 Jun; 27(6):1358-68. PubMed ID: 23247046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]